Sangamo Therapeutics Inc (NASDAQ:SGMO) has a beta value of 1.24 and has seen 1.75 million shares traded in the last trading session. The company, currently valued at $174.32M, closed the last trade at $0.84 per share which meant it gained $0.01 on the day or 1.41% during that session. The SGMO stock price is -76.19% off its 52-week high price of $1.48 and 65.48% above the 52-week low of $0.29. If we look at the company’s 10-day average daily trading volume, we find that it stood at 1.81 million shares traded. The 3-month trading volume is 13.98 million shares.
The consensus among analysts is that Sangamo Therapeutics Inc (SGMO) is Hold stock at the moment, with a recommendation rating of 2.12. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 2 out of 3 have rated it as a Hold, with 1 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.03.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Sangamo Therapeutics Inc (NASDAQ:SGMO) trade information
Sporting 1.41% in the green in last session, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the SGMO stock price touched $0.84 or saw a rise of 3.67%. Year-to-date, Sangamo Therapeutics Inc shares have moved 54.10%, while the 5-day performance has seen it change 7.20%. Over the past 30 days, the shares of Sangamo Therapeutics Inc (NASDAQ:SGMO) have changed 3.29%. Short interest in the company has seen 18.16 million shares shorted with days to cover at 5.48.
Wall Street analysts have a consensus price target for the stock at $12, which means that the shares’ value could jump 93.0% from current levels. The projected low price target is $5.0 while the price target rests at a high of $19.0. In that case, then, we find that the current price level is -2161.9% off the targeted high while a plunge would see the stock gain -495.24% from current levels.
Sangamo Therapeutics Inc (SGMO) estimates and forecasts
Figures show that Sangamo Therapeutics Inc shares have outperformed across the wider relevant industry. The company’s shares have gained 54.07% over the past 6 months, with this year growth rate of 20.34%, compared to 17.40% for the industry. Revenue growth from the last financial year stood is estimated to be -69.20%.
7 analysts offering their estimates for the company have set an average revenue estimate of 17.94M for the current quarter. 7 have an estimated revenue figure of 15.31M for the next ending quarter. Year-ago sales stood 10.4M and 2.04M respectively for this quarter and the next, and analysts expect sales will grow by 72.50% for the current quarter and -69.20% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -15.96% over the past 5 years.
SGMO Dividends
Sangamo Therapeutics Inc is expected to release its next earnings report in November this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Sangamo Therapeutics Inc (NASDAQ:SGMO)’s Major holders
Insiders own 2.28% of the company shares, while shares held by institutions stand at 42.10% with a share float percentage of 43.08%. Investors are also buoyed by the number of investors in a company, with Sangamo Therapeutics Inc having a total of 157.0 institutions that hold shares in the company. The top two institutional holders are WASATCH ADVISORS LP with over 20.09 million shares worth more than $7.2 million. As of 2024-06-30, WASATCH ADVISORS LP held 11.1403% of shares outstanding.
The other major institutional holder is ARMISTICE CAPITAL, LLC, with the holding of over 14.06 million shares as of 2024-06-30. The firm’s total holdings are worth over $5.04 million and represent 7.7963% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Wasatch Ultra Growth Fund and Wasatch Microcap Fund . As of Jun 30, 2024 , the former fund manager holds about 5.67% shares in the company for having 11.82 shares of worth $9.89 million while later fund manager owns 5.29 shares of worth $4.43 million as of Jun 30, 2024 , which makes it owner of about 2.54% of company’s outstanding stock.
